ITCI Intra-Cellular Total Business Assets

Intra-Cellular Therapies (ITCI) focuses on developing small-molecule therapies for bipolar disorders and schizophrenia, mitigating patent risks by expanding the scope of drug applications. Serving as the primary valuation tool, this chart on GURU.Markets illustrates total assets, which amount to 1047.41. High profitability is driven by exclusive rights to the Caplyta formula, while stable revenue is based on the long-term administration of medications for chronic pathologies.

To protect capital from market volatility, analyzing business scale is critical, which in the case of Intra-Cellular Therapies (ITCI) is confirmed by the transition from R&D to the commercialization of the patented Caplyta. The current value of 1047.41 reflects the total resource value reverse-calculated via ROA, where the structure of all company resources demonstrates asset utilization efficiency for profit generation, minimizing investment risks amid explosive sales growth.